Identification of AIF1 as a protein target of notoginsenosides in brain tissue of mice with intracerebral hemorrhage based on hapten immunoaffinity fishing technique
Feiyan Chen , Wei Qin , Qianlin Li , Chu Li , Cuihua Chen , Lin Chen , Qi Yao , Zhu Zhu , Yunan Zhao
{"title":"Identification of AIF1 as a protein target of notoginsenosides in brain tissue of mice with intracerebral hemorrhage based on hapten immunoaffinity fishing technique","authors":"Feiyan Chen , Wei Qin , Qianlin Li , Chu Li , Cuihua Chen , Lin Chen , Qi Yao , Zhu Zhu , Yunan Zhao","doi":"10.1016/j.jgr.2025.04.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Intracerebral hemorrhage (ICH) is a deadly stroke with high mortality or disability. Although recent research has demonstrated the efficacy of <em>Panax notoginseng</em> in ICH therapy, it is unclear which proteins may be targeted to achieve these advantages.</div></div><div><h3>Methods</h3><div>First, we generated polyclonal antibodies against notoginsenosides by immunizing rats with a ginsenoside Rh1-mcKLH conjugate. Second, the potential target proteins of notoginsenosides in brain tissue of ICH mice were identified using LC-MS-based hapten immunoaffinity fishing (HIAF). Third, the disease target databases and these proteins intersected. Fourth, biolayer interferometry (BLI), molecular docking, and site-directed mutagenesis were performed to validate allograft inflammatory factor 1 (AIF1) as a protein target of notoginsenosides. Last, bioinformatics analysis was performed to examine AIF1's biological characteristics.</div></div><div><h3>Results</h3><div>A potential protein target of notoginsenosides, AIF1, was found by intersecting the identified protein targets with the disease target databases via LC-MS-based HIAF. BLI analysis revealed that Compound K (CK) and AIF1 had the highest direct interaction, with an average shift value of 0.1091 nm. Subsequently, site-directed mutagenesis, molecular docking, and BLI kinetic analysis demonstrated that CK specifically bound to AIF1 with an affinity value of 4.33 ± 0.17E-6 M, with a significant reliance on residues L122 and E125. Bioinformatics analysis showed that AIF1 and its directly interacting proteins were associated with microglial activation.</div></div><div><h3>Conclusion</h3><div>Our study proposed a new technology for screening natural small molecule protein targets, and successfully identified AIF1 as a protein target of notoginsenosides, providing a chemical and biological basis for further research into targeting AIF1 to treat ICH.</div></div>","PeriodicalId":16035,"journal":{"name":"Journal of Ginseng Research","volume":"49 4","pages":"Pages 451-459"},"PeriodicalIF":6.8000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ginseng Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1226845325000387","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Intracerebral hemorrhage (ICH) is a deadly stroke with high mortality or disability. Although recent research has demonstrated the efficacy of Panax notoginseng in ICH therapy, it is unclear which proteins may be targeted to achieve these advantages.
Methods
First, we generated polyclonal antibodies against notoginsenosides by immunizing rats with a ginsenoside Rh1-mcKLH conjugate. Second, the potential target proteins of notoginsenosides in brain tissue of ICH mice were identified using LC-MS-based hapten immunoaffinity fishing (HIAF). Third, the disease target databases and these proteins intersected. Fourth, biolayer interferometry (BLI), molecular docking, and site-directed mutagenesis were performed to validate allograft inflammatory factor 1 (AIF1) as a protein target of notoginsenosides. Last, bioinformatics analysis was performed to examine AIF1's biological characteristics.
Results
A potential protein target of notoginsenosides, AIF1, was found by intersecting the identified protein targets with the disease target databases via LC-MS-based HIAF. BLI analysis revealed that Compound K (CK) and AIF1 had the highest direct interaction, with an average shift value of 0.1091 nm. Subsequently, site-directed mutagenesis, molecular docking, and BLI kinetic analysis demonstrated that CK specifically bound to AIF1 with an affinity value of 4.33 ± 0.17E-6 M, with a significant reliance on residues L122 and E125. Bioinformatics analysis showed that AIF1 and its directly interacting proteins were associated with microglial activation.
Conclusion
Our study proposed a new technology for screening natural small molecule protein targets, and successfully identified AIF1 as a protein target of notoginsenosides, providing a chemical and biological basis for further research into targeting AIF1 to treat ICH.
期刊介绍:
Journal of Ginseng Research (JGR) is an official, open access journal of the Korean Society of Ginseng and is the only international journal publishing scholarly reports on ginseng research in the world. The journal is a bimonthly peer-reviewed publication featuring high-quality studies related to basic, pre-clinical, and clinical researches on ginseng to reflect recent progresses in ginseng research.
JGR publishes papers, either experimental or theoretical, that advance our understanding of ginseng science, including plant sciences, biology, chemistry, pharmacology, toxicology, pharmacokinetics, veterinary medicine, biochemistry, manufacture, and clinical study of ginseng since 1976. It also includes the new paradigm of integrative research, covering alternative medicinal approaches. Article types considered for publication include review articles, original research articles, and brief reports.
JGR helps researchers to understand mechanisms for traditional efficacy of ginseng and to put their clinical evidence together. It provides balanced information on basic science and clinical applications to researchers, manufacturers, practitioners, teachers, scholars, and medical doctors.